Active	Status	Sponsor type	Region	Phase	Filter
2 Active 0 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Anti-CD22 CAR-T Cells / Beijing Boren Hospital
NCT04340167: Study of Anti-CD22 CAR-T Cells Treating Leukemia Children	Recruiting	2	100	RoW	Autologous humanized anti-CD22 chimeric antigen receptor T cells	Beijing Boren Hospital	Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoblastic Leukemia	05/24	10/24
ChiCTR2000028793: Single-center, single-arm study for autologous fully humanized CD22-CAR T cells in the treatment of refractory / relapsed acute B lymphoblastic leukemia	Not yet recruiting	1	10		CD22-CART cells	Beijing Boren Hospital; Beijing Boren Hospital, Self-raised	Blood disease